Treatment-resistant schizophrenic patients

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 9, 1996, Pages 35-40

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE;

CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; ELECTROCONVULSIVE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANCE ABUSE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; HUMANS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0029825886     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Cole JO, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: controlled studies. In: Solomon T, ed. Psychiatric Drugs. New York, NY: Groller and Stratton; 1966:153-180
2. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Md: Williams & Wilkins; 1968
3. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-768
4. McEvoy JP, Hogarty G, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher neuroleptic dose. Arch Gen Psychiatry 1991;48:739-745
5. Van Putten T, Marder SR, Mintz J. A controlled-dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758
6. Rifkin A, Doddi S, Karagi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991;48:166-170
7. Kinon BJ, Kane JM, John C, et al. Treatment of neuroleptic resistant schizophrenia relapse. Psychopharmacol Bull 1993;29:309-314
8. Kendall RE, Cooper JE, Gourlay AG, et al. The diagnostic criteria of American and British psychiatrists. Arch Gen Psychiatry 1971;25:123-130
9. Regier DA, Farmer ME, Ray DS, et al. Co-morbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-2518
10. Shaner A, Khalsa ME, Roberts LJ, et al. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993;150:758-762
11. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
12. Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-1188
13. May PRA. Treatment of Schizophrenia. New York, NY: Science House; 1968
14. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
15. Turkelsen KG, Grosser RC. Estimating clozapine's cost to the nation. Hosp Community Psychiatry 1990;41:863-869
16. Essock SM, Hargreaves WA, Dohn FA, et al. Clozapine eligibility among state hospital patients. Schizophr Bull. In press
17. Quitkin F, Rifkin A, Klein D. Very high dosage vs standard dosage fluphenazine in schizophrenia: a double-blind study of non-chronic treatment-refractory patients. Arch Gen Psychiatry 1975;32:1276-1281
18. Prien RF, Cole JO. High dose of chlorpromazine in chronic schizophrenia. Arch Gen Psychiatry 1968;18:482-495
19. Bjorndal N, Bjerre M, Gerlach J, et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology (Berl) 1980;67:17-23
20. Remington G, Pollack B, Voineskos G, et al. Acutely psychotic patients receiving high-dose haloperidol therapy. J Clin Psychopharmacol 1993;13: 41-45
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-535
22. Shalev A, Hermesh H, Rothberg J, et al. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 1993;87: 86-91
23. Claghorn J, Honigfeld G, Abuzzahab FS, et al. The risks and benefits of clozapine vs chlorpromazine. J Clin Psychopharmacol 1987;7: 377-384
24. Fischer-Cornelssen KA, Ferner UJ. An example of European multi-centered trials: multi-spectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-39
25. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789-796
26. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
27. Andreasen NC. A Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1983
28. Kane JM, Marder SR, Schooler N, et al. Efficacy of clozapine vs haloperidol in a long-term clinical trial: preliminary results. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR361:152-153
29. Meltzer HY. New insights into schizophrenia through atypical antipsychotic drugs. Neuropsychopharmacology 1988;1:193-196
30. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287
31. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
32. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
33. Heinrich K, Klieser E, Lehmann E, et al. Risperidone vs clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18: 129-137
34. Bondolfi G, Bauman P, Patris M, et al. A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 24, 1995; Miami, Fla. Abstract NR485:185
35. Carman JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenia and schizoaffective patients. J Clin Psychiatry 1981;42:124-128
36. Growe GA, Crayton JW, Klass DB, et al. Lithium in chronic schizophrenia. Am J Psychiatry 1979;136:454-455
37. Small JG, Kellams JJ, Milstein V, et al. A placebo controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975;132:1315-1317
38. Schulz SC, Odbert C, Thompson P, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic patients. Presented at the New Clinical Drug Evaluation Unit annual meeting; June 1993; Boca Raton, Fla
39. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217-245
40. Kane JM. Drug therapy of schizophrenia. N Engl J Med. In press